
On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.
The phase IIIa trial, called Oasis 1, comes at a time when Novo Nordisk is already experiencing huge US demand for its newly-launched obesity drug Wegovy. In its own phase III trials, this drug demonstrated an average weight loss of 17-18 percent in participants without type 2 diabetes, and the two drugs are based on the same active ingredient, semaglutide - though Wegovy is administered via injection.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app